BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 1746900)

  • 21. Mycosis fungoides and the Sézary syndrome.
    Kim YH; Hoppe RT
    Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis.
    Smith BD; Wilson LD
    Oncology (Williston Park); 2003 Sep; 17(9):1281-8. PubMed ID: 14569854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of ras p21 and myc p62 oncoproteins in small cell and non small cell carcinoma of the lung.
    Spandidos DA; Zakinthinos S; Petraki C; Sotsiou F; Yiagnisis M; Dimopoulos AM; Roussos C; Field JK
    Anticancer Res; 1990; 10(5A):1105-14. PubMed ID: 2173469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Langerhans cells and their precursors with S100 protein in mycosis fungoides.
    Igisu K; Watanabe S; Shimosato Y; Kukita A
    Jpn J Clin Oncol; 1983 Dec; 13(4):693-702. PubMed ID: 6196502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
    Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
    Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
    Jarrousse V; Quereux G; Marques-Briand S; Knol AC; Khammari A; Dreno B
    Eur J Dermatol; 2006; 16(6):636-41. PubMed ID: 17229603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Mycosis fungoides and Sézary syndrome. A retrospective study of 60 patients with correlation between histologic classification and survival time].
    Hödl S
    Z Hautkr; 1986 Jul; 61(14):993-1013. PubMed ID: 3751216
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
    Schappell DL; Alper JC; McDonald CJ
    Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mycosis fungoides in childhood and adolescence with clonal T-cell receptor gamma gene rearrangement. Two cases].
    Krokowski M; Winzer M; Lange K; Thorns C; Gafumbegete E; Feller AC; Merz H
    Hautarzt; 2003 Jun; 54(6):536-40. PubMed ID: 12759739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal Langerhans cells in mycosis fungoides and Sézary syndrome.
    Matejka M; Konrad K
    Wien Klin Wochenschr; 1983 Dec; 95(23):847-52. PubMed ID: 6670281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical features of cutaneous T-cell lymphoma.
    Abel EA
    Dermatol Clin; 1985 Oct; 3(4):647-64. PubMed ID: 2878755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas.
    Bunn PA; Lamberg SI
    Cancer Treat Rep; 1979 Apr; 63(4):725-8. PubMed ID: 445521
    [No Abstract]   [Full Text] [Related]  

  • 34. Expression of ras and myc oncogenes in human hepatocellular carcinoma and non-neoplastic liver tissues.
    Tiniakos D; Spandidos DA; Kakkanas A; Pintzas A; Pollice L; Tiniakos G
    Anticancer Res; 1989; 9(3):715-21. PubMed ID: 2548435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
    López-Lerma I; Estrach MT
    J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Morphometric study of lymphoid cells in mycosis fungoides and its simulators.
    Sinha AK; Singh MK; Dinda AK; Ramam M
    Indian J Pathol Microbiol; 2003 Jan; 46(1):28-33. PubMed ID: 15027714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
    Fulop V; Mok SC; Genest DR; Szigetvari I; Cseh I; Berkowitz RS
    J Reprod Med; 1998 Feb; 43(2):101-10. PubMed ID: 9513871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation.
    Roberts AA; Amano M; Felten C; Galvan M; Sulur G; Pinter-Brown L; Dobbeling U; Burg G; Said J; Baum LG
    Mod Pathol; 2003 Jun; 16(6):543-51. PubMed ID: 12808059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.